HRQOL Not Affected by Cytoreductive Surgery Plus HIPEC in Ovarian CancerMarch 26th 2023
According to Vadim Gushchin, MD, treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy should not be limited by concerns of how it may impact a patient’s health-related quality of life.
Long-Term Survival Benefit in Muscle-Invasive Urothelial Cancer Impacted by NivolumabFebruary 18th 2023
Extended follow-up findings of the phase 3 CheckMate 274 study further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.
ctDNA Serves as Biomarker for Early Response Assessment in Advanced CRCJanuary 23rd 2023
Compared with other tumor biomarkers, circulating tumor DNA may be ideal for early response assessment and have potential to enable use of adaptive clinical study designs in the future for patients with advanced colorectal cancer.
Camizestrant Bests Fulvestrant in HER2̶̶-Negative Advanced Breast Cancer SubsetDecember 8th 2022
Treatment with various camizestrant monotherapy doses lead to survival benefit compared with fulvestrant in a post-menopausal patient population diagnosed with estrogen receptor–positive, HER2-negative advanced breast cancer.
Enzalutamide/Abiraterone Acetate/Prednisolone Combo in mHSPC Not RecommendedSeptember 11th 2022
Androgen deprivation therapy plus abiraterone acetate and prednisolone resulted in a clinically meaningful overall survival benefit, but this in combination with enzalutamide fell short in patients with metastatic hormone-sensitive prostate cancer.
Benefit of Maintenance Rucaparib in Ovarian Cancer Seen Across SubgroupsSeptember 11th 2022
Maintenance rucaparib (Rubraca) induced a progression-free survival (PFS) improvement in patients with newly diagnosed ovarian cancer compared with placebo, which was also seen across all prespecified subgroups.
Survival Benefit Seen With Frontline Tremelimumab/Durvalumab/Chemo in Some mNSCLCAugust 9th 2022
The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.
Neoadjuvant Chemoimmunotherapy Shows Significant Survival Benefit in Stage III NSCLCAugust 8th 2022
Treatment with nivolumab and chemotherapy in patients with stage IIIA/B non–small cell lung cancer yielded significantly improved survival and responses, according to data from the phase 2 NADIM II study.
Use of Neoadjuvant Chemoimmunotherapy Supported in Stage IIIA NSCLCAugust 7th 2022
Using neoadjuvant chemoimmunotherapy to treat patients with stage IIIA resectable non–small cell lung cancer based on differences between pathologic complete responders and non–pathologic complete responders is supported by the phase 2 NADIM trial.
Long-Term OS Data for Axi-Cel Hint Short-Term EFS is a Surrogate End Point for R/R LBCLApril 24th 2022
According to a long-term analysis of the ZUMA-1 study, the overall survival rate yielded by axicabtagene ciloleucel may support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.
Lenvatinib with Transarterial Chemoembolization May be Efficacious, Safe First-Line Treatment Option for Advanced HCCJanuary 22nd 2022
Patients with advanced hepatocellular carcinoma achieved notable improvements in survival and responses following treatment with transarterial chemoembolization and lenvatinib.
Improved Survival Outcomes in Advanced RCC Seen with First-Line Immunotherapy, But Benefit Yet to Be Determined in Favorable-Risk DiseaseSeptember 16th 2021
While the benefit is yet to be determined in those with favorable-risk disease, patients with advanced renal cell carcinoma experienced improvements in both progression-free and overall survival after being treated with first-line immunotherapy vs sunitinib.
MRD-Based Consolidation Therapy With Dara-KRd Lead to Rapid Responses in Newly Diagnosed MyelomaSeptember 12th 2021
Rapid responses and tolerable safety was shown with minimal residual disease–based consolidation therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.